CARsgen Satri-cel Phase I Data at ESMO 2025: Early Signal in Adjuvant Pancreatic Cancer
October 20, 2025 | 16:09
Preliminary response rates suggest cell therapy may extend beyond haematology, although durability metrics remain necessary to assess true clinical benefit.
Mobile Version